This phase II trial studies the effect of probiotic on microbiome in invasive breast cancer patients. A probiotic, called BIOHM, is a food supplement that is believed to balance bacteria and fungi in the body. Understanding the association of microorganisms with breast cancer may enable new ways to prevent, diagnose, and treat breast cancer.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04362826.
Locations matching your search criteria
United States
Ohio
Cleveland
Case Comprehensive Cancer CenterStatus: Approved
Contact: Zahraa AlHilli
Phone: 216-444-3024
PRIMARY OBJECTIVES:
I. To determine the efficacy profile of the novel probiotic.
II. To analyze bacteriome and mycobiome profiles as well as polymicrobial biofilm composition from breast tissue after consumption of the probiotic and stool before and after consumption of the probiotic.
III. To compare quality of life (QoL) via standardized European Organization for Research and Treatment of Cancer (EORTC) instruments of those receiving novel probiotic to placebo.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I: Patients receive probiotic BIOHM orally (PO) once daily (QD) for 6 weeks in the absence of disease progression or unacceptable toxicity.
GROUP II: Patients receive placebo PO QD for 6 weeks in the absence of disease progression or unacceptable toxicity.
Trial PhasePhase II
Trial Typesupportive care
Lead OrganizationCase Comprehensive Cancer Center
Principal InvestigatorZahraa AlHilli